Time trends of cancer incidence and mortality in Catalonia during 1993–2007

Clinical and Translational Oncology - Tập 16 - Trang 18-28 - 2013
R. Clèries1,2, L. Esteban1, J. Borràs3,4, R. Marcos-Gragera5,6,7, A. Freitas8, M. Carulla3, M. Buxó5,6, A. Puigdefàbregas8, Á. Izquierdo5,6, R. Gispert8, J. Galceran3, J. Ribes1,2
1Registre de Càncer de Catalunya, Pla Director d’Oncologia (GENCAT). IDIBELL, Hospital Duran i Reynals, Barcelona, Spain
2Departament de Ciències Clíniques, Universitat de Barcelona, Barcelona, Spain
3Registre de Càncer de Tarragona, Fundació Lliga Per a la Investigació i Prevenció del Càncer, Reus, Spain
4Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain
5Unitat d’Epidemiología i Registre de Càncer en Girona (UERCG), Institut d’Investigació Biomèdica Girona Josep Trueta (IDIBGI), Girona, Spain
6Institut Català d’Oncologia (ICO), Girona, Spain
7Departament d’Infermeria, Universitat de Girona (UdG), Girona, Spain
8Departament de Salut, Servei d’Informació i Estudis (GENCAT), Barcelona, Spain

Tóm tắt

To describe time trends of cancer in Catalonia, Spain, during the period 1993–2007. Data have been provided by two population-based cancer registries, Girona and Tarragona, and the Catalan mortality registry. Cancer incidence in Catalonia has been estimated through modeling methods using data from these health structures. During 2003–2007, there were 20,042 cancer cases and 9,842 deaths per year among men and 13,673 new cancer cases and 5,882 deaths among women. The most frequent incident cancers among men were prostate (N = 4,258), lung (N = 3,021), colorectal (N = 3,007) and bladder (N = 2,238), whereas among women they were breast (N = 3,907), colorectal (N = 2,088), corpus uteri (N = 734) and lung (N = 527). During 1993–2007, age-standardized incidence rates (ASIRs) rose 1.2 % per year among men [prostate (6.3 %), testis (5.7 %), kidney (2.9 %), liver (2.2 %) and colorectal (2.1 %)]. ASIRs decreased for stomach (−2.9 %), oral cavity and pharynx (−2.8 %), larynx (−2.7 %) and esophagus (−2 %). Among women, ASIRs only rose for lung (5.2 %), kidney (3.1 %), oral cavity and pharynx (2.6 %) and thyroid (1.6 %). ASIRs decreased for corpus uteri (−2.3 %), stomach (−1.7 %) and ovary (−1.6 %). Cancer mortality decreased −1.3 % per year among men and −2.1 % among women during the same period. Among men, the decrease of incidence/mortality of tobacco-related tumors was related to a reduction of smoking prevalence. Among women, the stabilization of breast cancer incidence and the rise of lung cancer incidence are similar to that observed in most European regions. These results allow assessing the effectiveness of public health strategies and they pose new frontiers for cancer control in Catalonia.

Tài liệu tham khảo

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81. Cleries R, Ribes J, Buxo M, Ameijide A, Marcos-Gragera R, Galceran J, et al. Bayesian approach to predicting cancer incidence for an area without cancer registration by using cancer incidence data from nearby areas. Stat Med. 2012;10(31):978–87. Ribes J, Cleries R, Buxo M, Ameijide A, Valls J, Gispert R. Predictions of cancer incidence and mortality in Catalonia to 2015 by means of Bayesian models]. Med Clin (Barc). 2008;131(Suppl 1):32–41. Sanchez MJ, Payer T, De Angelis R, Larranaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;05(Suppl 3:iii):30–6. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M et al, editors. Cancer Incidence in Five Continents, Vol. IX. Lyon: IARC Scientific Publications; 2007. World Health Organization. International Classification of Diseases, ninth revision. Geneva: WHO; 1977. World Health Organization. International Statistical Classification of Diseases and Related Health problems, tenth revision. Geneva: WHO; 1992. Esteban L, Cleries R, Galvez J, Pareja L, Escriba JM, Sanz X, et al. REGSTATTOOLS: freeware statistical tools for the analysis of disease population databases used in health and social studies. BMC Public Health. 2013;13(1):201. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: gLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. Malvezzi M, Bertuccio P, Levi F, la Vecchia C, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol. 2013;24(3):792–800. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92. Izquierdo A, Gispert R, Saladie F, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: breast cancer. Med Clin (Barc). 2008;131(Suppl 1):50–2. Pollan M, Pastor-Barriuso R, Ardanaz E, Arguelles M, Martos C, Galceran J, et al. Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst. 2009;101(22):1584–91. Cleries R, Martinez JM, Moreno V, Yasui Y, Ribes J, Borras JM. Predicting the change in breast cancer deaths in Spain by 2019: a Bayesian approach. Epidemiology. 2013;24(3):454–60. Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, la Vecchia C. The decline in breast cancer mortality in Europe: an update (to 2009). Breast. 2012;21(1):77–82. Ribes J, Navarro M, Cleries R, Esteban L, Pareja L, Binefa G, et al. Colorectal cancer mortality in Spain: trends and projections for 1985–2019. Eur J Gastroenterol Hepatol. 2009;21(1):92–100. Borras JM, Pareja L, Peris M, Espinas JA. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: colorectal cancer. Med Clin (Barc). 2008;131(Suppl 1):58–62. Manchon-Walsh P, Borras JM, Espinas JA, Aliste L. Variability in the quality of rectal cancer care in public hospitals in Catalonia (Spain): clinical audit as a basis for action. Eur J Surg Oncol. 2011;37(4):325–33. Malvezzi M, Bosetti C, Rosso T, Bertuccio P, Chatenoud L, Levi F, et al. Lung cancer mortality in European men: trends and predictions. Lung Cancer. 2013;80(2):138–45. Borras JM, Pinol JL, Izquierdo A, Borras J. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: lung cancer. Med Clin (Barc). 2008;131(Suppl 1):53–7. Schiaffino A, Fernandez E, Kunst A, Borrell C, Garcia M, Borras JM, et al. Time trends and educational differences in the incidence of quitting smoking in Spain (1965–2000). Prev Med. 2007;45(2–3):226–32. Lopez MJ, Fernandez E, Perez-Rios M, Martinez-Sanchez JM, Schiaffino A, Galan I, et al. Impact of the 2011 Spanish smoking ban in hospitality venues: indoor secondhand smoke exposure and influence of outdoor smoking. Nicotine Tob Res. 2013;15(5):992–6. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289–93. Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8. Marcos-Gragera R, Pollan M, Chirlaque MD, Guma J, Sanchez MJ, Garau I, et al. Attenuation of the epidemic increase in non-hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3:iii):90–6. Clèries R, Martínez JM, Escribà JM, Esteban L, Pareja L, Borràs JM, et al. Monitoring the decreasing trend of testicular cancer mortality in Spain during 2005–2019 through a Bayesian approach. Cancer Epidemiology. 2010;34(3):244–56. Ribes J, Pareja L, Esteban L, Cleries R. Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985–2019: liver cancer. Med Clin (Barc). 2008;131(Suppl 1):83–7. Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191–9.